BioSpace News Archive

Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, provides a corporate update on a series of advancements for the company, including the completion of its reverse merger earlier this month in an all-stock transaction.

aTyr Pharma, Inc. today announced multiple presentations at the International Union of Biochemistry and Molecular Biology’s 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to take place June 4 – 9 in Ontario, Canada.

Bionano Genomics, Inc. announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded and tumor tissue.

Vaxart, Inc. (Nasdaq: VXRT) today announced that the last subject has completed dosing in the Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, recently hosted Congressman Scott Peters for a tour of the RNA manufacturing facility at Wateridge Circle in San Diego.

AAVantgarde Bio, a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral vector platforms for large gene delivery, announced the closing of a €61 million Series A financing.

Linnaeus Therapeutics, Inc. today announced the presentation of clinical data from its phase 1 dose-expansion study of LNS8801 as a monotherapy and in combination with pembrolizumab in metastatic uveal melanoma at the 2023 ASCO Annual Meeting.

AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023.

W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with five-year follow-up (NCT05489588) to evaluate the investigational GORE® VIAFORT Vascular Stent for the treatment of symptomatic iliofemoral venous obstruction.

SYBLEU Inc., a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, has begun trading on the OTC PINK markets under the symbol SYBE.